Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases, today announced that management will
present at the H.C. Wainwright Global Investment Conference being
held May 23 through May 26, 2022.
The prerecorded presentation will become
available on Tuesday, May 24, 2022 at 7:00 a.m. ET and can be
accessed by visiting the Events and Presentations section of the
Company’s website: https://ir.protaratx.com. The webcast will be
archived for 90 days following the presentation.
About Protara
Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Sep 2023 to Sep 2024